Issue of Shares
![](https://tracker.live.rns-distribution.com/track.live-rns/4836815_786a6156230e67e0eb54d832e6c71176.png)
("Renalytix" or the "Company")
Issue of Shares
After settlement of the repayment, the principal remaining under the convertible bond will be reduced by
1,052,422 new ordinary shares of
An application has been made to the
Total voting rights
Following Admission, the Company will have 94,833,900 Ordinary Shares in issue with each share carrying the right to one vote. The Company has no Ordinary Shares held in treasury. The total number of voting rights in the Company following Admission will therefore be 94,833,900.
For further information, please contact:
|
|
|
Via Walbrook PR |
|
|
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
|
|
|
|
|
Tel: 020 7597 4000 |
|
|
|
|
|
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
|
Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 |
|
|
|
|
|
Tel: 415-389-6400 or investors@renalytix.com |
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the